Publications A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells Incorporating a Chlorotoxin Tumor-targeting Domain for Patients with MMP2+ Recurrent or Progressive Glioblastoma Read More » August 2021
Press Releases Chimeric licenses novel solid tumor CAR T therapy from world-renowned cell therapy centre the University of Pennsylvania Read More » July 2021
Events and Presentations Corporate Presentation: Exclusive Licensing of CDH17 CAR T Cell Therapy from the University of Pennsylvania Read More » July 2021
Press Releases Dr Li Ren, a Senior CAR T Executive from BMS, joins Chimeric Therapeutics as Vice President, Technical Operations. Read More » June 2021